Merck & Co., Inc. (BVMF:MRCK34)

Market Cap	1.11T
Revenue (ttm)	346.63B
Net Income (ttm)	89.39B
Shares Out	n/a
EPS (ttm)	35.34
PE Ratio	12.36
Forward PE	8.66
Dividend	1.56 (2.85%)
Ex-Dividend Date	Jun 13, 2025

Volume	3,311
Average Volume	6,147
Open	56.94
Previous Close	57.18
Day's Range	54.59 - 57.07
52-Week Range	51.60 - 83.92
Beta	0.40
RSI	44.82
Earnings Date	Jul 29, 2025

About Blueprint Medicines

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: MRCK34

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.